NCT07327905 Intravenous Lidocaine Infusion Versus Intravenous Dexmedetomidine Infusion During Sleeve Gastrectomy
| NCT ID | NCT07327905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alexandria University |
| Condition | Bariatric Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-12-26 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-12-26 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although laparoscopic (LAP) bariatric surgery is minimally invasive. Following any laparoscopic procedure, patients typically experience the peak of postoperative pain within the first 24 hours. This intense pain gradually subsides, with significant relief usually occurring by the 2nd or 3rd postoperative day. The initial peak and subsequent decline in pain intensity highlight the importance of effective early pain management strategies to ensure patient comfort and recovery during this critical period. Inadequate management of postoperative pain can result in serious complications. Lidocaine is increasingly recognised as a vital adjunct in managing perioperative pain. Its efficacy extends beyond traditional local anaesthetic applications, as it also demonstrates analgesic, anti-hyperalgesic, and anti-inflammatory properties. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with hypnotic, sedative, anxiolytic, sympatholytic, and analgesic effects, while causing minimal respiratory depression
Eligibility Criteria
Inclusion Criteria: * Age: 20-50 years, both sexes. * American Standards Association (ASA) physical status class II to III. * Body mass index (BMI) 35-50 kg m-². Exclusion Criteria: * Cardiac conduction disorders. * Cardiomyopathy. * Chronic opioid use. * Allergy to the studied medications. * Pregnancy and breastfeeding.
Contact & Investigator
sarah m elgamal, MD
PRINCIPAL INVESTIGATOR
Alexandria University
Frequently Asked Questions
Who can join the NCT07327905 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 50 Years, studying Bariatric Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07327905 currently recruiting?
Yes, NCT07327905 is actively recruiting participants. Contact the research team at sarahelgamal1990@yahoo.com for enrollment information.
Where is the NCT07327905 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT07327905 clinical trial?
NCT07327905 is sponsored by Alexandria University. The principal investigator is sarah m elgamal, MD at Alexandria University. The trial plans to enroll 40 participants.